- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Questionnaire Administration
- Procedure: Biospecimen Collection
- Drug: Placebo Administration
- Procedure: Bone Marrow Aspiration
- Dietary supplement: Piperine Extract (Standardized)
- Procedure: Bone Marrow Biopsy
- Dietary supplement: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement
Detailed Description
PRIMARY OBJECTIVES:
I. To compare the change in inflammatory cytokine levels in study patients treated with curcumin versus placebo over a 12-month follow-up period.
II. To compare the change in symptomatology in study patients treated with curcumin versus placebo over a 12-month follow-up period.
SECONDARY OBJECTIVES:
I. To investigate the effect on variant allele frequency (VAF) of baseline mutations in study patients treated with curcumin versus placebo.
II. To investigate the effect on methylation patterns in study patients treated with curcumin versus placebo.
III. To evaluate the effect on peripheral blood cells in study patients treated with curcumin versus placebo.
IV. To assess the safety of curcumin for patients with CCUS/LR-MDS and symptomatic MPN who do not require disease-modifying therapy.
EXPLORATORY OBJECTIVE:
I. To investigate the correlation between inflammatory cytokine levels and symptom scores in study patients treated with curcumin versus placebo.
OUTLINE: Patients are randomized to 1 of 2 arms.
Arm I: Patients receive curcumin/demethoxycurcumin/bisdemethoxycurcumin-containing supplement (C3 complex)/piperine extract (standardized) (Bioperine) orally (PO) twice daily (BID) for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
Arm II: Patients receive placebo PO BID for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up annually for up to 10 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christine Duran
- Phone Number: 323-865-0371
- Email: duran_c@med.usc.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- USC / Norris Comprehensive Cancer Center
-
Contact:
- Christine Duran
- Phone Number: 323-865-0371
- Email: duran_c@med.usc.edu
-
Principal Investigator:
- Casey L. O'Connell, MD
-
Los Angeles, California, United States, 90033
- Recruiting
- Los Angeles General Medical Center
-
Contact:
- Christine Duran
- Phone Number: 323-865-0371
- Email: duran_c@med.usc.edu
-
Principal Investigator:
- Casey L. O'Connell, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18
- Eastern Cooperative Oncology Group (ECOG) =< 2
- Ability to understand and willingness to sign a written informed consent
Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria
- Presence of at least one symptom measurable using the MPN-/Symptom Assessment Form (SAF) with a severity greater than 3
- MPN patients determined to have stable disease undergoing surveillance and unlikely to require initiation of new cytoreductive therapy (i.e., hydroxyurea, ruxotinib, interferon within the study period); patients on a stable dose of hydroxyurea for at least 6 months who meet the other inclusion/exclusion criteria may be included
A diagnosis of CCUS or LR-MDS
- CCUS defined as persistent cytopenia for > 6 months (hemoglobin [Hgb] < 11.3 g/dL [7 mmol/L] in women and Hgb < 12.9 g/dL [8 mmol/L] in men, platelet < 150 x 10^9/L or neutrophils < 1.8 x 10^9/L), normal cytogenetics, presence of detectable MDS associated mutations and bone marrow morphology non-diagnostic of MDS or any other malignancies
- LR-MDS as defined by WHO 2016 diagnosis criteria
- Minimum baseline symptom score of 25 in the fatigue section of the symptom questionnaire
Exclusion Criteria:
- Patients with intake of curcumin as a dietary supplement, including multivitamin and unwillingness to quit more than 24 hours before study start
- Patients with inability to understand and adhere to information given
- Patients receiving active treatment for another malignancy except with hormonal therapy for a malignancy considered to be in remission or growth factors (erythropoietin, granulocyte colony-stimulating factor [G-CSF] and luspatercept)
- Patients with intermediate or high-risk MDS
- Patients must not be pregnant or nursing
- Patients must not be on any oral or intravenous steroid or any other anti-inflammatories (ibuprofen > 200mg/week or 400mg/month, naproxen of any dose, > 325mg aspirin daily, any herbal anti-inflammatory concoction of any dose)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (C3 Complex/Bioperine)
Patients receive C3 complex/Bioperine PO BID for 12 months in the absence of disease progression or unacceptable toxicity.
Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
|
Ancillary studies
Undergo collection of blood samples
Other Names:
Undergo bone marrow aspiration
Given PO
Other Names:
Undergo bone marrow biopsy
Other Names:
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO BID for 12 months in the absence of disease progression or unacceptable toxicity.
Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
|
Ancillary studies
Undergo collection of blood samples
Other Names:
Given PO
Other Names:
Undergo bone marrow aspiration
Undergo bone marrow biopsy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in peripheral blood levels of inflammatory cytokines
Time Frame: At baseline, 3 months, and 12 months
|
Interleukin (IL) 1beta, IL-6, IL-18, transforming growth factor-beta, and tumor necrosis factor-alpha will be assessed.
Mean inflammatory cytokine changes in the treatment group will be compared to that of the control group.
A two-sided two-sample unequal-variance t-test will be applied to compare the difference of the mean of changes at 12-months from the baseline measurement between the two arms, respectively.
P-values from the test and the 95% confidence interval of the estimated difference will be reported for each of the inflammatory cytokines.
|
At baseline, 3 months, and 12 months
|
Mean change in symptom scores for clonal cytopenia of undetermined significance and low risk myelodysplastic syndrome patients
Time Frame: At baseline, 3 months, 12 months
|
Symptoms scores will be assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version 3 (EORTC-QLQ-C30 version 3).This is a validated tool for assessing health-related quality of life in cancer patients.
The questionnaire is composed of both multi-item scales and single-item measures.
These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.
Scores range from 0 to 100.
A high scale score represents a higher response level.
A high score for a functional scale represents a high/healthy level of functioning.
A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems.(no symptom) to 10 (worst possible symptom).
|
At baseline, 3 months, 12 months
|
Mean change in symptom scores for myeloproliferative neoplasm (MPN) patients
Time Frame: At baseline, 3 months, 12 months
|
MPN-related symptoms will be assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Possible scores range from 0 (no symptom) to 10 (worst possible symptom).
|
At baseline, 3 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the variant allele frequency of mutated clones
Time Frame: After 12 months of treatment
|
Both parametric methods i.e., the two-sample t-test and the non-parametric Wilcoxon rank sum test (with no assumption on the distribution of the data) will be applied.
|
After 12 months of treatment
|
Change in the deoxyribonucleic acid methylation pattern
Time Frame: After 12 months of treatment
|
Both parametric methods i.e., the two-sample t-test and the non-parametric Wilcoxon rank sum test (with no assumption on the distribution of the data) will be applied.
|
After 12 months of treatment
|
Change in peripheral blood cell counts
Time Frame: After 12 months of treatment
|
Peripheral blood cell counts will include absolute neutrophil count, hemoglobin, and platelets.
Change in peripheral blood cell counts will be compared to pretreatment.
Both parametric methods i.e., the two-sample t-test and the non-parametric Wilcoxon rank sum test (with no assumption on the distribution of the data) will be applied.
|
After 12 months of treatment
|
Safety of curcumin in patients with CCUS/LR-MDS and symptomatic MPN
Time Frame: Every 2 weeks for the first month of treatment, every month for the following 2 months, then every 3 months for a total of 12 months.
|
Will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
|
Every 2 weeks for the first month of treatment, every month for the following 2 months, then every 3 months for a total of 12 months.
|
Change in the rate of transfusion requirement measured
Time Frame: Up to 10 years
|
Will be measured by the number of units required per 8-week period.
Both parametric methods i.e., the two-sample t-test and the non-parametric Wilcoxon rank sum test (with no assumption on the distribution of the data) will be applied.
|
Up to 10 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Casey L O'Connell, MD, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Precancerous Conditions
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Neoplasms
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Thrombocytosis
- Thrombocythemia, Essential
- Myeloproliferative Disorders
- Polycythemia Vera
- Polycythemia
- Cytopenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Cytochrome P-450 Enzyme Inhibitors
- Curcumin
- Piperine
Other Study ID Numbers
- 9L-23-1 (Other Identifier: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2023-06976 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden